Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:REXN

Rexahn Pharmaceuticals (REXN) Stock Price, News & Analysis

Rexahn Pharmaceuticals logo

About Rexahn Pharmaceuticals Stock (NASDAQ:REXN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.81
$2.24
52-Week Range
N/A
Volume
2,579 shs
Average Volume
162,968 shs
Market Capitalization
$8.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive REXN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rexahn Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

REXN Stock News Headlines

Aurinia Pharmaceuticals Inc AUPH
Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.tc pixel
Rexahn: Holes Galore in Serdaxin Data
See More Headlines

REXN Stock Analysis - Frequently Asked Questions

Rexahn Pharmaceuticals, Inc. (NASDAQ:REXN) posted its earnings results on Wednesday, August, 7th. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.95) by $0.34.

Shares of Rexahn Pharmaceuticals reverse split on Friday, April 12th 2019.The 1-12 reverse split was announced on Wednesday, April 10th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, April 11th 2019. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Rexahn Pharmaceuticals investors own include TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), CorMedix (CRMD), SELLAS Life Sciences Group (SLS), Dynavax Technologies (DVAX), Imunon (CLSN) and AcelRx Pharmaceuticals (ACRX).

Company Calendar

Last Earnings
8/07/2019
Today
8/28/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:REXN
CIK
1228627
Fax
N/A
Employees
5
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$8.64 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-72.60%
Return on Assets
-55.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.37
Quick Ratio
3.37

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.48 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
4,483,000
Free Float
N/A
Market Cap
$8.11 million
Optionable
Optionable
Beta
0.98
The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:REXN) was last updated on 8/28/2025 by MarketBeat.com Staff
From Our Partners